As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large …

REHABILITATION IN PATIENTS WITH LYMPHOMA: AN OVERVIEW OF SYSTEMATIC
REVIEWS - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

In patients with treatment-naive diffuse large B-cell lymphoma (DLBCL), the POLARIX study
(A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab …

Limited data are available regarding treatment patterns, healthcare resource utilization
(HCRU), treatment costs and clinical outcomes for patients with diffuse large B-cell …

Follicular lymphoma (FL) is a common B-cell malignancy characterized by relatively indolent
growth and incurability with an expected lifetime course of serial intermittent treatment …

Background Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an
emergent disease that threatens patients with texturized breast implants. Major concerns …

Background Few studies have estimated the real-world economic burden such as all-cause
and follicular lymphoma (FL)-related costs and health care resource utilization (HCRU) in …

Introduction Financial toxicity is a developing research area to quantify the financial stress
experienced by patients and caregivers, as well as the mechanisms by which they manage …

Background Diffuse large B‐cell lymphoma (DLBCL) represents the most common subtype
of non‐Hodgkin lymphoma in the US, but current real‐world data are limited. This study was …

We retrospectively analyzed treatment patterns and healthcare costs among patients
diagnosed with diffuse large B-cell lymphoma (DLBCL) during each line of therapy (LOT) …